The analysis included 405 patients divided into five groups according to the molecular subtype of breast cancer: luminal A (n = 130), luminal B HER2-negative (n = 100), luminal B HER2-positive (n = 96), HER2-positive (n = 36), and triple-negative breast cancer (TNBC). Here, ERBB2 is linked to triple-negative breast carcinoma.